Women naturally secrete more GH pulses per day than men but have a shorter GH half-life. This means women can have lower IGF-1 despite more frequent GH pulsation, which affects how sermorelin response is interpreted.
Sermorelin therapy in women requires a different clinical lens than in men. The interaction between estrogen, thyroid function, and the GH axis means that the same sermorelin dose can produce very different IGF-1 responses depending on the hormonal context. Women in perimenopause or menopause, where estrogen and progesterone are declining alongside GH, are the most common female candidates and also the most likely to benefit from a protocol that addresses both axes.
- Start with sermorelin monotherapy and establish a baseline IGF-1 response before adding any peptide
- Ipamorelin is the preferred GHRP addition: it does not raise cortisol or prolactin
- CJC-1295 has a 6 to 8-day half-life; suited for less frequent dosing protocols
- BPC-157 addresses tissue repair through a separate mechanism from the GH axis
- Stack decisions should be made by a physician based on 90-day IGF-1 data, not started at initiation
How Estrogen Affects IGF-1
Estrogen has a dual effect on the GH axis. At the level of the pituitary, estrogen enhances GH secretion by increasing pituitary sensitivity to GHRH. At the level of the liver, estrogen reduces IGF-1 production by partially blocking GH signaling. The net result is that women with normal estrogen levels often produce more GH than men but show lower IGF-1 readings because estrogen blunts hepatic IGF-1 output.
Women with low estrogen, as in menopause, lose both the pituitary-stimulating effect and the hepatic blocking effect. The result varies: some postmenopausal women have lower IGF-1 because GH secretion declines without estrogen support; others have normal IGF-1 because the hepatic block is removed. This is why a full female hormone panel at intake provides more clinical information than IGF-1 alone.
GH Decline in Perimenopause and Menopause
GH secretion begins declining in the early 30s for both sexes, but women experience a faster rate of decline during perimenopause due to the interaction between falling estrogen and GH pulsatility. The symptoms of GH decline, including poor slow-wave sleep, increased visceral fat, reduced lean mass, and low energy, overlap substantially with symptoms of estrogen and progesterone deficiency.
- GH decline and estrogen decline produce overlapping symptoms: separating them requires lab testing
- Sleep disruption in perimenopause has both a GH component and a vasomotor component
- Visceral fat accumulation in menopause reflects both falling estrogen and declining GH
- A baseline panel covering IGF-1, estrogen, progesterone, DHEA, cortisol, and thyroid is the correct starting point
Thyroid Function and Sermorelin Response
Hypothyroidism reduces the liver's ability to produce IGF-1 in response to GH stimulation. Women are 5 to 8 times more likely than men (per American Thyroid Association [3]) to develop hypothyroidism, and subclinical hypothyroidism is particularly common in perimenopause. A patient with undiagnosed low thyroid function may show poor IGF-1 response to sermorelin not because the GH axis is failing but because the liver cannot convert GH to IGF-1 efficiently.
Thyroid function should be confirmed before interpreting a flat IGF-1 response to sermorelin. TSH, free T3, and free T4 are the relevant markers. Treating subclinical hypothyroidism before or alongside sermorelin will improve IGF-1 response.
Dosing Differences in Women
Women typically require slightly lower sermorelin doses than men to achieve equivalent IGF-1 responses, consistent with greater pituitary sensitivity to GHRH stimulation. Starting at 100 mcg nightly and titrating based on the 90-day IGF-1 result is the appropriate approach for most female patients. Doses above 200 mcg in women are less commonly required and carry a higher risk of water retention than in men at the same dose.
Combined Sermorelin and Hormonal Protocols
Women whose intake panel shows both low IGF-1 and low estrogen benefit from addressing both axes. Sermorelin restores GH pulsatility. Bioidentical estrogen replacement restores the pituitary sensitization effect that estrogen normally provides. Running both protocols simultaneously produces better outcomes than sermorelin alone in estrogen-deficient women. This requires a physician experienced in female hormone optimization rather than a standard sermorelin telehealth provider.
Women with normal estrogen who show low IGF-1 and symptoms of GH decline are appropriate candidates for sermorelin monotherapy. The combination protocol is specifically indicated when estrogen deficiency is confirmed alongside GH axis decline.
Realistic Expectations for Women
Women on sermorelin show measurable IGF-1 elevation within 2 weeks of starting therapy (Khorram et al., 1997 [5]). Body composition changes from GHRH-analog therapy develop over a 6-month protocol (Stanley 2015 tesamorelin data). Women on combined sermorelin and HRT protocols may show different IGF-1 response patterns because of estrogen's dual effect: oral estrogen suppresses hepatic IGF-1 synthesis [2], so transdermal HRT is generally preferred when managing the GH axis alongside HRT.
Bottom Line
Women are appropriate candidates for sermorelin therapy when IGF-1 is low or low-normal and symptoms of GH decline are present. Thyroid function must be confirmed before interpreting lab results or concluding non-response. Women in perimenopause or menopause with concurrent estrogen deficiency benefit most from a platform that evaluates both axes at intake and can prescribe both protocols under one clinical plan.
Frequently Asked Questions
Is sermorelin safe for women in perimenopause?
Yes. Women in perimenopause are among the most appropriate candidates for sermorelin. The declining GH axis in perimenopause occurs alongside falling estrogen and progesterone, producing overlapping symptoms. A full intake panel covering IGF-1, estrogen, progesterone, DHEA, cortisol, and thyroid is the correct starting point. Women with both low IGF-1 and low estrogen benefit most from a provider who can evaluate and address both axes.
Can sermorelin be combined with estrogen therapy?
Yes. Women with documented low IGF-1 alongside low estrogen can take sermorelin and bioidentical estrogen replacement concurrently. Oral estrogen blunts hepatic IGF-1 output more than transdermal estrogen, so transdermal forms are preferred when managing the GH axis alongside HRT. The combination requires a provider with experience managing both protocols simultaneously.
Does sermorelin interact with hormonal birth control?
Oral contraceptive pills contain synthetic estrogens that blunt hepatic IGF-1 production, similar to menopausal HRT. Women on OCPs may show lower IGF-1 responses to sermorelin than women who are not on hormonal contraception. This does not contraindicate sermorelin, but the prescribing physician should account for this when interpreting baseline IGF-1 and 90-day response data.
Should women have different lab tests than men before starting sermorelin?
Yes. A female intake panel extends beyond the IGF-1 draw that is the minimum for male patients. The recommended panel includes IGF-1, estradiol, progesterone, DHEA-S, cortisol, TSH, free T3, and free T4. Thyroid function matters because hypothyroidism, more common in women, reduces IGF-1 response and is often subclinical.
Can sermorelin cause irregular menstrual cycles?
Irregular menstrual cycles are not a documented or expected side effect of sermorelin at standard doses. The effect of sermorelin on menstrual regularity has not been established as a clinical concern at therapeutic doses. Women who notice cycle changes after starting sermorelin should report them to the prescribing physician for evaluation to rule out other causes.
References
- Growth hormone and aging (sex differences in GH secretion) Endotext (NCBI Bookshelf), 2020. NBK279056. https://www.ncbi.nlm.nih.gov/books/NBK279056/
- Contrasting effects of oral and transdermal routes of estrogen replacement therapy on 24-hour growth hormone (GH) secretion, insulin-like growth factor I, and GH-binding protein Journal of Clinical Endocrinology & Metabolism, 1991. PMID: 1991807. https://pubmed.ncbi.nlm.nih.gov/1991807/
- General Information: Thyroid disease prevalence in women thyroid.org, 2026. https://www.thyroid.org/media-main/press-room/
- Geref Prescribing Information (untreated hypothyroidism) RxList, 2008. https://www.rxlist.com/sermorelin-acetate-drug.htm
- Endocrine effects of GHRH-(1-29)-NH2 in age-advanced subjects JCEM, 1997. PMID: 9141536. https://pubmed.ncbi.nlm.nih.gov/9141536/
